Zydus Gets Final USFDA Nod for Arsenic Trioxide Inj | CORPORATE ETHOS

Zydus Gets Final USFDA Nod for Arsenic Trioxide Inj

By: | November 14, 2018
zydus-cadila

Nov 14: Drug maker Zydus Cadila on Wednesday said that it has received the final approval from the USFDA to market its Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL) single-dosevial (US RLD —TRISENOX@).

“Arsenic Trioxide is used to treat a type of leukemia (acute promyelocytic leukemia-APL) when other types of treatment (e.g., chemotherapy) have not worked well or no longer work,” te company said.

“It will be manufactured at Alidac Pharmaceuticals Ltd, the company’s wholly-owned subsidiary located at SEZ, Ahmedabad,” it added.

The group now has 228 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.